impact factor
logo
 

Targeted systemic DMARDs in psoriatic arthritis

 

The role of methotrexate in psoriatic arthritis: what is the evidence?


1, 2

 

  1. Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  2. Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. weisman@cshs.org

CER8987
2015 Vol.33, N°5 ,Suppl.93
PI 0094, PF 0097
Targeted systemic DMARDs in psoriatic arthritis

Free to view
(click on article PDF icon to read the article)

PMID: 26470718 [PubMed]

Received: 18/09/2015
Accepted : 18/09/2015
In Press: 15/10/2015
Published: 16/10/2015

Abstract

Methotrexate is a popular and widely used medication for the treatment of psoriatic arthritis. Herein we review the body of evidence for its use and examine its benefits as well as its limitations, both as a monotherapy and in combination with other DMARDs and biological drugs.

Rheumatology Article